A new analysis presented at the American Heart Association’s (AHA) Scientific Sessions 2025 suggests that chronic melatonin use may not be as benign as widely believed
A new analysis presented at the American Heart Association’s (AHA) Scientific Sessions 2025 suggests that chronic melatonin use may not be as benign as widely believed
Older adults with chronic insomnia were 40% more likely to develop mild cognitive impairment or dementia over a median 5.6 years compared with older adults without insomnia, according to a study published in Neurology.
Older adults with chronic insomnia were 40% more likely to develop mild cognitive impairment or dementia over a median 5.6 years compared with older adults without insomnia, according to a study published in Neurology.
While regularity in day-to-day sleep patterns appears beneficial for cognitive function, sleep patterns that are rigid or highly regular may not be optimal in terms of serum brain-derived neurotrophic factor (BDNF).
While regularity in day-to-day sleep patterns appears beneficial for cognitive function, sleep patterns that are rigid or highly regular may not be optimal in terms of serum brain-derived neurotrophic factor (BDNF).
Real-world data presented at the American Academy of Neurology (AAN) 2026 Annual Meeting reported improvements in migraine-related cognitive symptoms with eptinezumab (VYEPTI).
Real-world data presented at the American Academy of Neurology (AAN) 2026 Annual Meeting reported improvements in migraine-related cognitive symptoms with eptinezumab (VYEPTI).
Teleneurological ward rounds were found noninferior to conventional on-site ward rounds in subacute inpatient stroke care, according to prospective study findings.
Teleneurological ward rounds were found noninferior to conventional on-site ward rounds in subacute inpatient stroke care, according to prospective study findings.
High-dose influenza vaccination may confer additional neuroprotective benefit beyond standard-dose formulations, according to results from a new, large retrospective cohort study published in Neurology.
High-dose influenza vaccination may confer additional neuroprotective benefit beyond standard-dose formulations, according to results from a new, large retrospective cohort study published in Neurology.
According to recent findings, early extubation after thrombectomy did not improve 90-day functional independence compared with delayed extubation in patients with acute ischemic stroke.
According to recent findings, early extubation after thrombectomy did not improve 90-day functional independence compared with delayed extubation in patients with acute ischemic stroke.
A phase 3 clinical trial found that tavapadon, an investigational oral D1/D5 dopamine agonist, was effective as an adjunctive therapy to levodopa for motor fluctuations in Parkinson disease (PD).
A phase 3 clinical trial found that tavapadon, an investigational oral D1/D5 dopamine agonist, was effective as an adjunctive therapy to levodopa for motor fluctuations in Parkinson disease (PD).
A prospective cohort study found that suicidality at the time of focal epilepsy diagnosis was linked to a more than twofold increased risk of future antiseizure medication (ASM) treatment resistance.
A prospective cohort study found that suicidality at the time of focal epilepsy diagnosis was linked to a more than twofold increased risk of future antiseizure medication (ASM) treatment resistance.
Patients with migraine are at 2 times the risk for depression or anxiety compared to those without migraine, according to a large nationwide Swedish cohort study published in The Journal of Headache and Pain.
Patients with migraine are at 2 times the risk for depression or anxiety compared to those without migraine, according to a large nationwide Swedish cohort study published in The Journal of Headache and Pain.
The pivotal Phase III FENhance 1 trial of fenebrutinib met its primary endpoint in relapsing multiple sclerosis (RMS), demonstrating statistically significant and clinically meaningful reductions in relapse activity.
The pivotal Phase III FENhance 1 trial of fenebrutinib met its primary endpoint in relapsing multiple sclerosis (RMS), demonstrating statistically significant and clinically meaningful reductions in relapse activity.
In a prospective cohort of 159,347 US adults, higher adherence to 6 healthy dietary patterns was associated with lower risk of subjective cognitive decline (SCD).
In a prospective cohort of 159,347 US adults, higher adherence to 6 healthy dietary patterns was associated with lower risk of subjective cognitive decline (SCD).
Ublituximab provided sustained reductions in disease activity and disability progression over 5 years in adults with relapsing multiple sclerosis (RMS), according to open-label extension study findings.
Ublituximab provided sustained reductions in disease activity and disability progression over 5 years in adults with relapsing multiple sclerosis (RMS), according to open-label extension study findings.
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data
To view accreditation information/faculty disclosures for the program, click
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data
To view accreditation information/faculty disclosures for the program, click